Gsk Plc-spon Adr (GSK) Held by Superinvestors
GSK PLC-SPON ADR (GSK) is currently held by 7 superinvestors tracked by InsiderSet, with a combined reported market value of approximately $2.55B based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026.
Dodge & Cox Stock Fund is currently the largest disclosed institutional shareholder of GSK tracked by InsiderSet, reporting ownership valued at approximately $2.53B in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $2.39B, representing an estimated loss of -5.55% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed GSK value among the investors covered in this analysis. Major shareholders include Dodge & Cox Stock Fund, Kahn Brothers Group, Hillman Value Fund, and several other long-term asset managers with concentrated positions in GSK PLC-SPON ADR (GSK).
This page ranks the largest institutional GSK shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | V. D. Dodge, E. M. Cox | 1.32% | 48,197,514 | $2,526,513,684 | $2,386,258,918 | -$140,254,766 | -5.55% |
| Kahn Brothers Group | Thomas Graham, Alan, Irving Kahns | 1.31% | 158,438 | $8,305,319 | $7,844,265 | -$461,054 | -5.55% |
| Hillman Value Fund | Mark A. Hillman | 3.51% | 92,383 | $4,842,717 | $4,573,882 | -$268,835 | -5.55% |
| Tweedy, Browne Co All Funds (US) | B. Tweedy, Ch. Browne | 0.32% | 81,527 | $4,273,645 | $4,036,402 | -$237,243 | -5.55% |
| Sequoia Financial Advisors | 0.01% | 36,293 | $1,902,458 | $1,796,866 | -$105,592 | -5.55% | |
| Pzena Investment Management | Richard Pzena | 0.00% | 28,964 | $1,395,200 | $1,434,008 | +$38,808 | +2.78% |
| Causeway Capital Management | Sarah Ketterer | 0.00% | 7,163 | $375,470 | $354,640 | -$20,830 | -5.55% |
Frequently asked questions about GSK
Who are the largest superinvestors holding GSK?
The largest superinvestors holding GSK in the latest SEC Form 13F filings include Dodge & Cox Stock Fund, Kahn Brothers Group, Hillman Value Fund, Tweedy, Browne Co All Funds (US), and Sequoia Financial Advisors. InsiderSet ranks these superinvestors by their latest reported GSK position.
What does the GSK superinvestors page include?
This page tracks GSK positions reported by a curated group of notable institutional investors and fund managers through SEC Form 13F. GSK PLC-SPON ADR (GSK) on this page reflects disclosed 13F holdings among those superinvestors, not every institutional shareholder of the stock.
How many superinvestors hold GSK?
InsiderSet currently tracks 7 superinvestors reporting GSK holdings in the latest available 13F data. This is the curated set on this page, not the total number of institutions that own GSK.
How much GSK stock do superinvestors hold?
Superinvestors tracked by InsiderSet disclosed approximately $2.55B in GSK holdings for Q2 2026. This figure is reported 13F value as of the filing period, not necessarily today's market value, and it covers the curated superinvestors on this page rather than every institutional filer.
When were GSK superinvestor holdings last updated?
The latest GSK superinvestor holdings on InsiderSet are based on SEC Form 13F filings for the quarter ended June 30, 2026. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time holdings.
Are superinvestor GSK holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by these superinvestors as of the end of the reporting quarter. A superinvestor may have changed its GSK position after the reporting date.
Are superinvestors buying or selling GSK?
Buying and selling can be analyzed by comparing GSK positions across consecutive 13F reporting periods. InsiderSet's GSK Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View GSK ownership changes.
How have superinvestor GSK holdings changed over time?
InsiderSet tracks GSK holdings among these superinvestors across multiple 13F reporting periods, so holder counts, reported value, and reported shares can be compared over time.